287 related articles for article (PubMed ID: 31407414)
1. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
Gollnick H; Dirschka T; Ostendorf R; Kerl H; Kunstfeld R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):82-89. PubMed ID: 31407414
[TBL] [Abstract][Full Text] [Related]
2. Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Hasan ZU; Ahmed I; Matin RN; Homer V; Lear JT; Ismail F; Whitmarsh T; Green AC; Thomson J; Milligan A; Hogan S; Van-de-Velde V; Mitchell-Worsford L; Kentley J; Gaunt C; Jefferson-Hulme Y; Bowden SJ; Gaunt P; Wheatley K; Proby CM; Harwood CA
Br J Dermatol; 2022 Sep; 187(3):324-337. PubMed ID: 34988975
[TBL] [Abstract][Full Text] [Related]
3. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses.
Ulrich C; Johannsen A; Röwert-Huber J; Ulrich M; Sterry W; Stockfleth E
Eur J Dermatol; 2010; 20(4):482-8. PubMed ID: 20507841
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial.
Togsverd-Bo K; Halldin C; Sandberg C; Gonzalez H; Wennberg AM; Sørensen SS; Wulf HC; Haedersdal M
Br J Dermatol; 2018 Apr; 178(4):903-909. PubMed ID: 28796885
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
[TBL] [Abstract][Full Text] [Related]
7. Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety.
Martin GM; Stockfleth E
J Drugs Dermatol; 2012 May; 11(5):600-8. PubMed ID: 22527428
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
[TBL] [Abstract][Full Text] [Related]
9. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up.
Krawtchenko N; Roewert-Huber J; Ulrich M; Mann I; Sterry W; Stockfleth E
Br J Dermatol; 2007 Dec; 157 Suppl 2():34-40. PubMed ID: 18067630
[TBL] [Abstract][Full Text] [Related]
10. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses.
Akarsu S; Aktan S; Atahan A; Koç P; Özkan S
Clin Exp Dermatol; 2011 Jul; 36(5):479-84. PubMed ID: 21418281
[TBL] [Abstract][Full Text] [Related]
11. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
[TBL] [Abstract][Full Text] [Related]
12. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities.
Sotiriou E; Apalla Z; Maliamani F; Zaparas N; Panagiotidou D; Ioannides D
J Eur Acad Dermatol Venereol; 2009 Sep; 23(9):1061-5. PubMed ID: 19470041
[TBL] [Abstract][Full Text] [Related]
13. Bucher's indirect comparison of daylight photodynamic therapy with methyl aminolevulinate cream versus diclofenac plus hyaluronic acid gel for the treatment of multiple actinic keratosis.
Calzavara-Pinton P; Zane C; Pacou M; Szeimies RM
Eur J Dermatol; 2016 Oct; 26(5):487-492. PubMed ID: 27352420
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream.
Lee PK; Harwell WB; Loven KH; Phillips TJ; Whiting DA; Andres KL; Lee JH
Dermatol Surg; 2005 Jun; 31(6):659-64. PubMed ID: 15996416
[TBL] [Abstract][Full Text] [Related]
15. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
[TBL] [Abstract][Full Text] [Related]
16. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze).
Nelson C; Rigel D; Smith S; Swanson N; Wolf J
J Drugs Dermatol; 2004; 3(4):401-7. PubMed ID: 15303784
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
[TBL] [Abstract][Full Text] [Related]
18. Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.
Ahmady S; Jansen MHE; Nelemans PJ; Kessels JPHM; Arits AHMM; de Rooij MJM; Essers BAB; Quaedvlieg PJF; Kelleners-Smeets NWJ; Mosterd K
JAMA Dermatol; 2022 Jun; 158(6):634-640. PubMed ID: 35475852
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up.
Tschen EH; Wong DS; Pariser DM; Dunlap FE; Houlihan A; Ferdon MB;
Br J Dermatol; 2006 Dec; 155(6):1262-9. PubMed ID: 17107399
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
Quist SR; Gollnick HP
Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
